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The major (but not only) roles of the hemostatic system
are to maintain blood in a fluid state under physiologic
conditions and to seal a vessel wall defect in order to pre-
vent blood loss. Pathologically, bleeding or thrombosis
may occur if the hemostatic stimulus is unregulated,
either at the level of stimulatory or inhibitory pathways.
The balance of stimulatory and inhibitory pathways is
also well established for platelets. These specialized adhe-
sive cells play a key role in normal and pathological
hemostasis through their ability to rapidly adhere to sub-
endothelial matrix proteins and to other activated plate-
lets. Such platelet functions are strongly inhibited by
endothelium-derived prostacyclin and NO and their
cAMP/PKA- and cGMP/PKG-regulated pathways includ-
ing kinase targets such as VASP, IRAG, LASP and others
[1]. It is also well established that both stimulatory and
inhibitory platelet pathways interact at various levels rep-
resenting significant functional cross-talk. Recently, we re-
addressed one of the controversially discussed pathways,
the platelets NOS system. We discovered that human and
murine platelets do not express functional NOS proteins
and that platelet soluble guanylyl cyclase (sGC) is NOS-
independently activated by von Willebrand factor (VWF)
which may represent a new mechanism of feedback inhi-
bition [2]. The underlying mechanisms are currently stud-
ied using a recently established quantitative
phosphoproteomic approach. Initial data will be pre-
sented. As long-term goal, it is hoped that such studies
will establish new diagnostic and therapeutic approaches
with respect to platelet function and dysfunction, espe-
cially in the area of NO/cGMP signalling.
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